Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of AIN457 in ankylosing spondylitis
2009-011591-30Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Primary endpoints: Safety and tolerability and Immunogenicity of AIN457. Started Oct 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2009-011591-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011591-30.